Wolff C, Armas R, Krause P, Parraguez A, Ramón Soto J
Departamento de Medicina Occidente, Facultad de Medicina, Universidad de Chile, Hospital San Juan de Dios, Santiago de Chile.
Rev Med Chil. 1996 Apr;124(4):456-60.
Chloroquine may improve cutaneous symptoms and liver disease manifestations in patients with porphyria cutanea tarda.
To retrospectively analyze the effects of choloroquine in patients with porphyria cutanea tarda.
Five patients (one female), aged 45 to 65 years old, were studied. The duration of the disease ranged from 2 to 15 years. One patient was alcoholic and other was a hepatitis C virus carrier. All patients received chloroquine 125 mg twice weekly. Before, during and after treatment, cutaneous signs, serum bilirubin, hepatic enzymes and urine copro and uroporphyrin were assessed. Four patients were subjected to a liver biopsy before starting chloroquine.
All patients had increased levels of urine porphyrins, four had abnormal serum liver enzymes. All liver biopsies showed variable hemosiderosis, two patients had a chronic active hepatitis (one with cirrhosis), one a chronic persistent hepatitis and one had mild rague alterations. During chloroquine treatment, cutaneous symptoms improved in all patients, transaminases and gamma glutamyl transferase decreased. In three, urine uroporphyrin increased initially and normalized afterwards. Choloroquine was well tolerated.
Chloroquine improved cutaneous symptoms, urine uroporphyrin and serum liver enzyme levels in treated patients.
氯喹可能改善迟发性皮肤卟啉病患者的皮肤症状和肝脏疾病表现。
回顾性分析氯喹对迟发性皮肤卟啉病患者的疗效。
研究了5例患者（1例女性），年龄45至65岁。病程为2至15年。1例患者为酗酒者，另1例为丙型肝炎病毒携带者。所有患者每周两次服用125毫克氯喹。在治疗前、治疗期间和治疗后，评估皮肤体征、血清胆红素、肝酶以及尿粪卟啉和尿卟啉。4例患者在开始服用氯喹前接受了肝活检。
所有患者尿卟啉水平升高，4例患者血清肝酶异常。所有肝活检均显示不同程度的含铁血黄素沉着，2例患者有慢性活动性肝炎（1例伴有肝硬化），1例为慢性持续性肝炎，1例有轻度模糊改变。在氯喹治疗期间，所有患者的皮肤症状均有改善，转氨酶和γ-谷氨酰转移酶下降。3例患者尿卟啉最初升高，随后恢复正常。氯喹耐受性良好。
氯喹改善了接受治疗患者的皮肤症状、尿卟啉和血清肝酶水平。
